Validated HPLC procedures for the analysis of BMY-28090 in human plasma and urine

@article{Gaver2004ValidatedHP,
  title={Validated HPLC procedures for the analysis of BMY-28090 in human plasma and urine},
  author={Robert C. Gaver and George Deeb and Alice M. George},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2004},
  volume={25},
  pages={195-201}
}
SummaryThe compound BMY-28090 (elsamicin A) is a new fermentation product with antitumor properties, which has the same aglycone as chartreusin but contains two novel sugars. To define the disposition of BMY-28090 during phase I trials, HPLC procedures were developed and validated for the quantitation of the drug in human plasma and urine. To 1.0 ml plasma were added 0.5 ml 0.2M phosphate buffer (pH 8.0), 125 ng 1-naphthol (internal standard) in 25 μl MeOH and 5 ml ethyl acetate. After mixing… 
Emerging DNA topisomerase inhibitors as anticancer drugs.
  • W. Denny
  • Biology, Chemistry
    Expert opinion on emerging drugs
  • 2004
TLDR
This review covers 24 drugs that inhibit or poison the function of topoisomerase (topo) enzymes at various stages of clinical development, and finds that many of the latter class are at an early stage of development, despite a lack of detailed structural biology on the target enzymes.
Emerging DNA topoisomerase inhibitors as anticancer drugs
TLDR
This review covers 24 drugs that inhibit or poison the function of topoisomerase (topo) enzymes at various stages of clinical development, and finds that many of the latter class are at an early stage of development, despite a lack of detailed structural biology on the target enzymes.

References

SHOWING 1-9 OF 9 REFERENCES
Elsamicins, new antitumor antibiotics related to chartreusin. I. Production, isolation, characterization and antitumor activity.
TLDR
New antitumor antibiotics, elsamicin A and B, were isolated from the culture broth of an unidentified actinomycete strain J907-21 (ATCC 39417) and were found to be 10-30 times more potent than that of chartreusin in terms of minimum effective dose.
Experimental antitumor activity of elsamicin, a new antitumor antibiotic
  • Proc Am Assoc Cancer Res
  • 1986
lular uptake of elsamicin and DNA breakage in P 388 murine leukemia cells
  • Proc Am Assoc Cancer Res
  • 1987
Elsamicin A
  • Drugs Future
  • 1987
BMY - 28090 ( elsamicin ) , a new antitumor antibiotic related to chartreusin : isolation , chemistry and activity
  • 1985
Cellular uptake of elsamicin and DNA breakage in P388 murine leukemia cells
  • Proc Am Assoc Cancer Res
  • 1987
BMY-28090 (elsamicin), a new antitumor antibiotic related to chartreusin: isolation, chemistry and activity. In: Ishigami J (ed) Recent advances in chemotherapy
  • Proceedings of the International Congress on Chemotherapy., Anticancer section
  • 1985
Elsamicin and esperamicin: novel fermentation-derived cytotoxic antitumor agents with unique mechanisms of action
  • Proc Am Assoc Cancer Res
  • 1988